Post-transcriptional regulation plays a central role in cell differentiation and proliferation. Among the regulatory factors involved in this mechanism, Tristetraprolin (ZFP36 or TTP) is the prototype of a family of RNA-binding proteins that bind to adenylate and uridylate (AU)-rich sequences in the 3 ′ UTR of mRNAs, which promotes their physiological decay. Here, we investigated whether TTP correlates with tumor aggressiveness in breast cancer and is a novel prognostic factor for this neoplasia. By immunoblot analysis, we determined the amount of TTP protein in different breast cancer cell lines and found an inverse correlation between aggressiveness and metastatic potential. TTP mRNA levels were very variable among cells lines and did not correlate with protein levels. Interestingly, by sequencing the entire TTP coding region in Hs578T cells that do not express the TTP protein, we identified a synonymous polymorphism (rs3746083) that showed a statistically significant association with a lack of response to Herceptin/Trastuzumab in HER2-positive-breast cancer patients. Even though this genetic change did not modify the corresponding amino acid, we performed functional studies and showed an effect on protein translation associated with the variant allele with respect to the wild-type. These data underline the importance of synonymous variants on gene expression and the potential role of TTP genetic polymorphisms as a prognostic marker for breast cancer.
INTRODUCTION
In recent years, evidence has accumulated indicating that modulation of mRNA stability plays a central role in physiological cellular homeostasis (1) . As in the case of transcriptional control, the post-transcriptional fate of a given mRNA is governed by the interaction of specific mRNA sequences, such as adenylate and uridylate (AU)-rich elements (AREs), with specific trans-acting factors such as mRNA-binding proteins or microRNA. mRNA decay is regulated by the relative amount of RNA-stabilizing and RNA-destabilizing factors, which are in turn regulated at several levels by environmental stimuli and cellular signaling pathways. Among the mRNA-destabilizing proteins, Tristetraprolin, also named ZFP36 (zinc finger protein 36; MIM 190700), is one of the most important and best studied proteins. TTP is a member of a family of three human genes (ZFP36, ZFP36L1 and ZFP36L2) which are characterized by two tandemly repeated zinc finger motifs through which they bind to ARE elements in mRNA and mediate ARE-mediated mRNA decay (2) . TTP is an early response gene that accumulates very * To whom correspondence should be addressed at: University Nice-Sophia Antipolis IBDC, CNRS UMR 6543, Centre Antoine Lacassagne, 33, av. Valombrose, 06189 Nice, France. Tel: +33 492031231; Fax: +33 492031235; Email: gpages@unice.fr quickly after the stimulation of numerous cell types with several kinds of stimuli, including insulin and other growth factors, and stimulators of innate immunity such as endotoxin lipopolysaccharide (LPS) (3) . The activated protein is highly phosphorylated at serine residues mainly due to the activity of p38-MAPK and, to a lesser extent, to the Ras/ ERK kinase cascade (4, 5) . It has been widely accepted that the phosphorylation level of the protein plays a crucial role in TTP activity, localization and stability, representing an important mechanism of post-translational control (5, 6) . In vivo and in vitro studies indicate that TTP is involved in the resolution phase of the inflammatory response by destabilizing the mRNA of many cytokines (2) . Mice deficient in TTP develop a severe inflammatory syndrome, including polyarticular arthritis, myeloid hyperplasia and autoimmunity (7) . This syndrome is largely due to the increased stability of the mRNA for TNF-alpha and results in enhanced expression of the cytokine (8) . Some other wellestablished targets of TTP include GM-CSF (9), cyclooxygenase 2 (10), VEGF (5), CXCL1 (11), IL8 (12) and the hypoxia-inducible factor-1alpha (HIF-1a) (13) . Together these examples suggest a complex relationship between TTP and cellular proliferation, apoptosis and angiogenesis and propose that TTP is a crucial key player in inflammation and tumor development. Moreover, several studies showed that TTP mRNA and protein levels were significantly reduced in glioma and in thyroid, lung, breast and colon cancer (12, (14) (15) (16) . Accordingly, all these studies suggest that loss of TTP expression can represent a selective advantage for cancer cells affecting key tumorigenic cell phenotypes such as cell proliferation and expression of angiogenic factors (VEGF and IL8). Breast cancer is the most common type of malignant cancer and is the leading cause of cancer-related deaths among women. Breast cancer cells are highly invasive and have a high metastatic potential. Despite significant advances in diagnosis and treatment, the incidence of breast cancer is increasing worldwide (17) . The aim of this work was to investigate the role played by TTP in the context of breast cancer progression and to investigate whether and which TTP-associated parameters (mRNA levels, protein expression, common polymorphisms or mutations) could be used as a prognostic factor in breast cancer. We tested the presence of the TTP protein and mRNA in several breast cancer cell lines (MDA231, Hs578T, MCF7, T47D) to examine the relationship between TTP expression and cancer aggressiveness. In addition, after sequencing the entire coding region of the gene in the same cell lines and tumor samples, we identified a synonymous polymorphism c.309C . T (rs3746083) in Hs578t, a TTP-negative cell line that does not change the corresponding amino acid (R103R). By performing genetic and functional studies, we show that this polymorphism may be associated with cancer prognosis and that a TTP deficiency is observed in this aggressive cell line. Moreover, we describe a negative effect of that mutation on translation efficiency of TTP mRNA. We show that regulation of the total amount of TTP protein is a key event in tumorigenesis and we suggest a potential role of the c.309C . T polymorphism as a breast cancer prognostic factor.
RESULTS

TTP, VEGF, IL8 expression in breast cancer cell lines
We analyzed several breast cancer cell lines, MDA231, Hs578T, MCF7, T47D, by immunoblotting for the protein levels of TTP. MDA231 and Hs578T are very aggressive cell lines, characterized by a mesenchymal phenotype, a lack of expression of oestrogen, progesterone and the HER2 receptors (the so-called triple negative phenotype), whereas MCF7 and T47D show a less aggressive, epithelial phenotype and expression of oestrogen, progesterone receptors without amplification of HER2 protein. Whereas TTP has a predicted size of 35 kDa, we observed different bands of 35-47 kDa in Raw.264.7 cells stimulated with LPS (a well-recognized model for studying TTP and its effect on the regulation of TNF alpha mRNA half-life; Supplementary Material, Fig. S1 ) (18) and bands of 45-47 kDa in breast cancer cell lines (Fig. 1A) . This finding is compatible with prior reports indicating modifications of the electrophoretic profile because of phosphorylation. These phosphorylation events implicate p38/mitogen-activated protein kinase and the extracellular signal-regulated kinases 1/2 (5,18). The altered electrophoresis of TTP was already observed in cancer cells including glioma (12) and breast cancer cells (15) and fibroblasts expressing a Raf:ER chimera (5) with commercial (12, 15) and home-made antibodies (5). We found that although MCF7 and T47D cells did express TTP at levels comparable with those of MCF10, an immortalized, nontumorigenic breast cell line, TTP expression was strongly reduced in MDA231 and Hs578T cells (Fig. 1A) . We investigated whether reduction of TTP protein expression could correlate with higher production of angiogenic factors such as VEGF and IL8 in triple negative (MDA231 and Hs578T) cells than in less aggressive cell lines (MCF7 and T47D). For this purpose, we performed real-time quantitative PCR, with mRNA, and enzyme-linked immunosorbent assay (ELISA), with secreted proteins in the cell supernatant of the four cell lines. We found that MDA231 and Hs578T cells have reduced expression of the TTP protein, but produced a high amount of VEGF and IL8 at both the mRNA and protein levels ( Fig. 1B and C) . These data underlie a correlation between TTP levels and breast tumor aggressiveness.
Modulation of TTP expression affects angiogenic factor expression in poorly or highly aggressive breast cancer cell lines
To further understand the correlation between TTP and angiogenic factors in breast cancer, we constructed stably transfected MDA231/Tet-Off cell clones expressing Myc-tagged TTP from a tetracycline-responsive cassette. As previously observed for HeLa/TTP cells, the Tet-Off model is more suitable for the study of genes involved in cell proliferation since it allows tight regulation of transgene expression and avoids selection of false-positive clones. Tetracycline potently inhibited expression of TTP, which was restored after the removal of tetracycline from the medium. We obtained one clone (PA15) with low inducible expression, one clone with moderate expression (PA48) and one clone with highly inducible expression of the TTP protein (PA1) (Fig. 2A) (Fig. 3B) , which is in agreement with our previous data showing the effect of the same shRNAs in melanoma cells (19) . Concomitant to the decrease in TTP, we found a significant increase in the levels of VEGF mRNA (1.14-fold increase, P ¼ 0.0006 for sh62.TTP; 1.38-fold increase, P ¼ 0.00003 for sh65.TTP) and IL8 mRNA (1.22-fold increase, P ¼ 0.003 for sh62.TTP; 1.32-fold increase, P ¼ 0.006 for sh65.TTP). These results confirmed the dose-dependent effect of TTP expression on VEGF and IL8 mRNA levels previously observed in MDA231 cells (Fig. 3C ). Effect of TTP on proliferation in breast cancer cells
Another tumorigenic phenotype that can be modulated by TTP expression is the proliferation rate of the tumor cells (14) . In two MDA-231 clones (PA1 and PA15), which express TTP at high and low levels, respectively, we found a decrease in the proliferation rate depending on TTP expression (Fig. 4A ). During proliferation of the MDA-231 clones (up to 4 days), we did not observe any morphological change and no increase in cell death or apoptosis, as reported for glioma or HeLa cells (12, 14) . Furthermore, we used the stable, MCF7-TTP knock-down clones (sh62-TTP and sh65-TTP) to confirm the effect of TTP expression on proliferation. Both clones (sh62-TTP and sh65-TTP) showed a significant increase in the proliferation rate according to a dose-dependent disappearance of TTP (Fig. 4B) . As previously described for VEGF and IL8 mRNA expression, we observed a dose-dependent effect of TTP on proliferation.
TTP expression in breast cancer
Taken together, our data strongly indicate that TTP levels are crucial in determining the production of two important angiogenic factors, VEGF and IL8, and in regulating cell proliferation in breast cancer. These results strongly agree with data in the literature, which demonstrated that TTP expression was frequently suppressed in breast cancers. Consequently, TTP has been proposed as a prognostic factor that is able to influence cancer patient outcome (14) . Since the possibility of using the TTP expression level as a breast cancer prognostic factor is very promising, we tested at the same time the relative amount of TTP mRNA and protein in our breast cancer cell lines to examine whether a correlation exists between TTP mRNA and protein levels. We tested MCF7, MDA-231, T47D and Hs578T cells and used human embryonic kidney cells (HEK293) as a negative control since these cells were described to be negative for TTP protein expression (20) . As shown in Figure 5A , TTP protein can be clearly detected in MCF7 and T47D cells, although it is absent or very weakly expressed in HEK293, MDA-231 and Hs578T cells. We analyzed TTP mRNA using the 2[ddC(T)] method with MCF7 cells as a reference control. In this way, we normalized TTP levels to MCF7 cells and obtained a null value for TTP-negative cells (HEK293). We found the lowest TTP mRNA levels in MDA-231 cells, whereas significant amounts of TTP mRNA were detected in MCF7 and T47D cells. Surprisingly, HS578T cells, which do not express the protein, showed highly detectable levels of TTP mRNA (Fig. 5B) . Our data showed a substantial lack of correlation between TTP mRNA and protein expression levels, a difference that may be due to a lack of translation efficiency.
Genetic analysis of the TTP gene
To further understand the lack of protein expression observed in Hs578T cells, we analyzed the sequence corresponding to the entire TTP mRNA (5 ′ UTR, coding region and 3 ′ UTR), 1 kb of the promoter region and the splice junctions on genomic DNA and used MCF7 cells as a control. We detected . T) that modifies the codon corresponding to arginine from CGC to a CGT (R103R). This SNP was previously reported to be associated with rheumatoid arthritis, an inflammatory condition corresponding to the clinical phenotype of TTP knock-out mice (2) . No other nucleotide variations were detected in the promoter region, the 5 ′ UTR and 3 ′ UTR and the splice junctions of the TTP gene. We designed a case -control study to assess the role played by the c.309C . T variant in breast carcinogenesis by studying a group of women with breast cancer (92 individuals) and a group of female controls (89 individuals). All patients had very aggressive tumors carrying an amplification of the HER2 gene (HER2-positive) and all cases were treated with Herceptin/Trastuzumab, a monoclonal antibody directed against HER2 (21). We found 13 heterozygote CT in the group of patients (CT heterozygote frequency ¼ 14.1%) and 5 heterozygote CT in the group of controls (CT heterozygote frequency ¼ 5.6%). The allelic frequencies of the C and T alleles, reported in Table 1 , revealed an increase in the variant T allele in the group of patients, but which did not reach statistical significance [P-x 2 test ¼ 0.1 confirmed by using P-Fisher's test ¼ 0.08, OR ¼ 2.7, 95% CI (0.9 -10.3)]. Moreover, we investigated whether the c.309C . T variant could be associated with other clinical parameters such as patient outcome or the survival rate. We did not find any correlation with the survival rate but we found a different distribution of the T allele with respect to the patients' response to Herceptin/Trastuzumab treatment. As reported in Table 2 , the variant T allele was clearly more frequent in the group of Herceptin/Trastuzumab-resistant patients than in the other group, with a statistical significant value [P-x 2 test ¼ 0.01 confirmed by using P-Fisher's test ¼ 0.01, OR ¼ 8.0, 95% CI (1.9 -33.4)]. Our data suggest that the synonymous polymorphism c.309C . T can have a functional effect on TTP expression and be related to a differential response to Herceptin/Trastuzumab treatment.
Functional analysis of the c.309C > T genetic variant
Considering the results obtained from genetic analysis, we investigated whether the c.309C . T variant can be responsible for the discrepancy between the mRNA and protein levels observed in Hs578T cells. First of all, we investigated whether the c.309C . T synonymous change could affect gene expression by interfering with mRNA stability or protein translation (22) . PCR analysis of full-length TTP cDNA obtained from Hs578T cells did not reveal the existence of anomalous alternative transcripts produced in these cells compared with wild-type MDA231 cells (Fig. 6A ). To check whether both wild-type and variant alleles were transcribed, we examined the presence of the SNP by both digestion analysis with the enzyme HhaI and by sequencing of PCR products from genomic DNA and cDNA obtained from Hs578T cells. Both techniques showed that the allele carrying the variant T allele was more expressed than the wild-type C allele of Hs578T cell cDNA ( Fig. 6A and B) . Since this difference in mRNA amounts may be attributed to a difference in mRNA half-life, DRB chase experiments were performed. Hence, the TTP-mRNA half-life was 31.5 min (+0.1) in MCF7 (TTP-positive), 22.2 min (+0.3) in MDA231 (TTP-negative) and 29.4 min (+2.6) in Hs578T (TTP-negative) cells (Fig. 6C) . The half-life differences are statistically significant between the Hs578T and MDA231 or MCF7 and MDA231 cells (P ¼ 0.009 and P ¼ 0.0001) but not between Hs578T and MCF7 cells (P ¼ 0.17), suggesting that the synonymous polymorphism c.309C . T does not affect mRNA stability.
The c.309C > T polymorphism decreases mRNA translational efficiency
The experiments described above showed a lack of correlation between mRNA and protein levels. Thus, we hypothesized a lower efficiency of translation of RNA carrying the C . T mutation. To functionally test this hypothesis, we performed an in vitro transcription and translation assay using a Myc-tagged TTP construct for both the wild-type and the mutated allele, and we clearly show that the wild-type construct was translated more than the variant (Fig. 7A) . To confirm these data, we set up an experimental model by cloning the two fulllength coding regions (the wild-type C allele, the mutated T allele) into the eukaryotic expression vector (pcDNA4/TO/ myc-His) to perform transient transfection in the TTP-negative cell line (HEK293). A luciferase construct was co-transfected as a control for transfection efficiency. Experiments with different amounts of TTP plasmid (100, 200 and 500 ng of plasmid DNA/10 5 cells) were performed to determine the optimal concentration of TTP that could not affect luciferase transcription and/or stability or induce massive cell death. No effect on cell death was observed but transfection of Table S1 ). Comparing only samples characterized by the same transfection efficiency, we showed that the wild-type TTP plasmid produced a higher amount of protein than the polymorphic one when 100 or 200 ng of expression plasmid was transfected (Fig. 7B ). These differences in amount of protein are not related to a difference in mRNA abundance since they are produced equivalently (Fig. 7B ). This first approach was completed by using bicistronic constructs in which each variant of TTP is the first cistron, and the second cistron is the firefly luciferase reporter gene. In between the two coding sequences, we placed the EMCV IRES sequence (Fig. 7C) . We performed transient transfection in the TTP-negative cell line HEK293. In these experiments, equal loading of western blots was normalized by the measure of firefly luciferase activity in each lysate. Cells transfected with the TTP variant construct showed poor TTP protein expression, whereas TTP wild-type constructs produced high levels of TTP protein (Fig. 7C) . These results strongly suggest that TTP mRNA carrying the C . T mutation is less efficiently translated.
To clearly demonstrate that this regulation was exerted through a translational regulation mechanism, we examined the association of wild-type and variant transcripts with polysomes (Fig. 8) . For this purpose, we evaluate the translation efficiency of the two TTP mRNAs species by using either MCF7 cells expressing wild-type TTP or Hs578T cells expressing the TTP variant. As shown in Figure 8 , wild-type TTP mRNAs from MCF7 cells are present in all the fractions, including the fractions containing heavy polysomes, indicating that this species can be efficiently translated. Conversely, TTP variant mRNAs from Hs578T cells were found to be recovered only in the free mRNA, monosome and disome fractions and showed a very poor association with heavy polysomes fractions (Fig. 8C and D) .
These data suggest for the first time that translation efficiency is a new way to regulate the steady-state levels of TTP. To investigate further the differences between the wild-type and variant TTP constructs, we performed a functional assay testing the effect of the two plasmids on the 3 ′ UTR of VEGF, a well-known TTP target, cloned downstream of the luciferase gene in the pGL2 vector (5) . Of note, when we transfected HEK293 cells with wild-type TTP, we observed a decrease in the luciferase activity compared with the control (pcDNA4/TO/myc-His empty vector), but no significant differences were obtained with the variant construct (Fig. 8E) . To validate our results, we checked whether transiently transfected TTP could modulate the half-life of endogenous TTP targets, VEGF (5) and cyclin D1 mRNAs (23) in HEK293 cells. As illustrated in Figure 8F , DRB pulse chase experiments showed that VEGF mRNA half-life is significantly shorter when the wild-type form of TTP is transfected compared with the half-life obtained after the transfection of the variant form (respectively, t 1/2 ¼ 120 + 5 versus t 1/2 ¼ 208 + 4 min). Figure 8G also shows that transfection of the variant form of TTP did not significantly affect cyclin D1 mRNA amounts after 3 h of DRB treatment, whereas transfection of the wild-type form of TTP significantly decreased them. This result suggests that, similar to VEGF, wild-type TTP decreased cyclin D1 mRNA half-life, whereas the variant form of TTP had no significant effect. Our data show that the variant and polymorphic sequences did not give the same translation efficiency in the in vitro and in vivo cellular contexts, and affect the mRNA decay of target genes.
DISCUSSION
In recent years, it has become widely accepted that TTP plays a crucial role in tumor progression. Data so far report that TTP is deficient in many cancer types and that restoration of TTP can suppress the invasive potential of cancer cells (12, 14) . To confirm previously established results (15), we analyzed TTP protein levels in four different breast cancer cell lines and examined the correlation between TTP deficiency and breast cancer invasiveness. To further our knowledge of the molecular mechanisms behind TTP induction and regulation in breast cancer, we took advantage of inducible TTP-overexpressing clones, obtained from the MDA231 breast cancer cell line, which did not express the TTP protein and had a very aggressive phenotype. An sh-RNA approach has also confirmed our hypothesis. To our knowledge, this is the first time that TTP inducible overexpression is obtained in a breast cancer cell line. It has been reported that TTP expression exerts a negative effect on proliferation and cell survival in glioma and cervical adenoma cells (12, 14) but nothing was known about its direct role in breast cancer cells. We observed a dose-dependent inhibitory effect on the proliferation rate after TTP-induction in MDA231 breast cancer cell lines, confirming findings in MCF7, which showed an increased growth rate after TTP-silencing. The effect of TTP on the cell cycle is probably due to the destabilizing effect that this protein might have on genes involved in cell-cycle control, through proteins such as cyclin D1 or a recently identified target, LATS2, which are both implicated in the control of cell growth and cycle progression (23 -24) . Our data also confirm the crucial role of TTP on angiogenesis by regulating expression of two major angiogenic factors, VEGF and IL8, as it has been shown in glioma (12) and in melanoma cells for IL8 (19) . Taken together, these data strongly indicate that TTP levels are critical for the biological behavior of breast cancer cells, by affecting both the production of angiogenic factors and the proliferation rate of the cells.
Having considered the crucial role played by TTP in tumor progression, we are tempted to speculate that TTP may act as a tumor-suppressor gene and that a deficiency in TTP may 
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Human Molecular Genetics, 2011, Vol. 20, No. 23 represent a key event in human carcinogenesis. Tumorsuppressors are genes that protect the cell from cancer development and are inactivated by mutations or epigenetic events, which favor tumorigenesis. The hypothesis that TTP is a tumor-suppressor gene is supported by the fact that TTP deficiency is particularly frequent in tumors of the thyroid, lung, ovary, uterus and breast and that low TTP mRNA levels were found to be associated with poor prognosis in breast cancer patients (14) . Focusing on breast cancer, at least two microarray studies demonstrated TTP down-regulation in both invasive and sporadic basal-like breast cancer samples compared with normal tissues (25, 26) . To investigate whether TTP could be considered a real tumor-suppressor gene, as proposed in a previous paper (14), we analyzed both mRNA and protein expression in breast cancer cell lines. By studying Hs578T, MDA231, MCF7 and T47D cells by qPCR and performing immunoblot analyses, we showed a high variability in TTP mRNA levels, which do not correlate with the amount of protein. We suggest that even though the analysis of TTP mRNA can be an indicator of a deficiency in TTP, this test should be coupled to protein analysis to avoid false-positive results and should be a truly reliable prognostic factor. To further the understanding of the discrepancy between the mRNA and protein levels observed in Hs578T cells, we found that these cells carry one synonymous substitution c.309C . T, which did not change the corresponding amino acid arginine. We focused our attention of this polymorphism for several reasons: (i) the C . T transition was reported to be associated with rheumatoid arthritis, an inflammatory condition which resembles the clinical phenotype of TTP knock-out mice (27) ; (ii) the variant T allele is rarely present in humans with a codon usage frequency of 4.5/1000 against 10.4/1000 of the wild-type CGC (Codon Usage Database, http://www.ka zusa.or.jp/codon) (28); (iii) the variant T allele is not conserved among species (27) ; (iv) synonymous changes have been reported to affect translation efficiency by interfering with both mRNA stability and the protein translation rate (29) (30) (31) ; (v) we showed that the T allele was more highly expressed at the cDNA level than at the C allele, becoming (32) . Furthermore, a silent point mutation may cause variations in the rate of translation due to differential abundances of the cognate tRNA(s) of each single-triplet or by inducing a ribosomal pause that leads to alternate folding pathways (33-35). Since we did not observe any effect on mRNA splicing, we focused our attention on the functional effect of the synonymous variant on TTP translation. Even though our artificial system cannot fully reflect physiological conditions, our results can provide useful clues to understand the causes of lack of TTP expression in Hs578T cells and the association of the variant T allele with Herceptin/Trastuzumab treatment response. If the T allele is associated with reduced translation in all the cells carrying this variant, the quite exclusive expression of the T allele in the cDNA of Hs578T cells can explain the lack of expression of TTP in this cell line. Even though differential transcription cannot be excluded, we hypothesized that the differential expression of the T allele is due to a different stability of the two transcripts. This was the case of the COMT gene for which a gene haplotype, divergent in synonymous changes, was associated with a more stable structure but lower protein levels due to messenger RNA local stem loop structures (29) . Although it is only informative, prediction of mRNA folding using the RNAfold program (http://rna.tbi.univie.ac.at/cgi-bin/RNAfold.cgi)
showed a more stable secondary structure of mRNA molecules corresponding to the variant T allele with respect to the wildtype C allele (data not shown). It is clear that the complete sequence of TTP regulatory regions such as the 5 ′ and 3 ′ UTR and the determination of the full haplotype of the TTP gene carrying the T variant in Hs578T cells will be very useful to understand the real situation in vivo. Our work confirms a crucial role for TTP in breast cancer progression but at the same time underlies the complexity of the study of TTP gene expression for basic and translational research.
MATERIALS AND METHODS
Plasmid constructs
For the MDA231 Tet-Off approach, the pREV-TTP construct was obtained by inserting a 1 kb DNA fragment corresponding to the coding region of TTP cDNA (5) within HindIII sites of a pREV plasmid (Clontech). The pcDNA4/TO/myc-HysA (Invitrogen, Trex-TTP) containing the wild-type and variant human TTP sequence was generated by amplifying a region of 1 kb directly from Hs578T cell cDNA with forward (5 ′ -CCACT CTCGGCCGACACCCC-3 ′ ) and reverse (5 ′ -GTCACTCA GAAACAGAGATGCG-3 ′ ) primers and inserting the fragment into the pCR2.1-TOPO vector, and TTP fragments were then inserted into pcDNA4/TO/myc-HysA within EcoRI sites. Two independent plasmid preparations were obtained for each construct. The TTP WT and variant (V) coding sequence was PCR-amplified with primers TTP-F-XbaI (5 ′ -AAAATCTA GACCATGGATCTGACTGCCATCTACGAG-3 ′ ) and 
The PCR fragments as well as the pCREL (36) were digested by XbaI and BglII and ligated together to give, respectively, the pCTTPwt and pCTTPvar bicistronic vectors.
RNA preparation and analysis by quantitative PCR
Total RNA was extracted with TRIzol reagent (Invitrogen). Two micrograms of total RNA was used for reverse transcription, using the Superscript First-Strand Synthesis System (QIAGEN, Hilden, Germany), with oligo(dT) to prime firststrand synthesis. For real-time PCR, TaqMan Gene Expression Assays (Applied Biosystems) and qPCR Core Kits (Eurogentec) were used. To calculate the relative expression of TTP, VEGF, IL8 mRNA in cell lines, the 2[ddC(T)] method was used (37) and normalization was carried out with RPLP0. To calculate the mRNA stability, 25 mg/ml of 5,6-dichloro-1-D-ribofuranosylbenzimidazole DRB was added to breast cancer cell lines in culture and the RNA was extracted at different times. The relative amount of each mRNA at time 0 before DRB addition was set to 100%.
Cell culture, transfection and luciferase assays
Breast cancer cell lines MDA231, Hs578T, MCF7, T47D, MCF10 and HEK293 were grown as previously described (5, 38) . RAW264.7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum in a humidified atmosphere of 5% CO 2 at 378C and stimulated with LPS (Sigma-Aldrich) at a concentration of 10 ng/ml. Validation of the TTP antibody was performed by SDS -polyacrylamide gel (PAGE) immunoblot analysis on protein extracts of RAW264.7 cells stimulated with LPS and with HEK293 cells, which do not express TTP, transfected with human TTP (20) (Supplementary Material, Fig. S1 ). Stable clones were obtained by transfecting the pREV-TTP plasmid with Lipofectamine TM 2000 (Invitrogen), and hygromycinresistant clones were screened by immunoblotting after tetracycline removal. Silencing of TTP in MCF7 cells was obtained by transfecting cells with lipofectamine and MISSION TM shRNA lentivirus plasmids (Sigma-Aldrich). Selection of resistant clones was performed by adding puromycin, and screening was performed by qPCR on selected clones.
The functional test for the TTP polymorphism was performed on HEK293 cells using the calcium phosphate method (5) . The assay was performed in duplicate with different amounts of pcDNA4/TO/myc-HysA carrying the wild-type and the variant TTP sequence (two independent preparations for each construct). At the same time, 300 ng of pGL3 luciferase expression plasmids were co-transfected as an independent control of the transfection efficiency in each well. The assay was performed as previously described (5). The transfection efficiency was calculated from the luciferase counts normalized to the amount of protein. Only cells that showed the same degree of transfection efficiency (difference,20%) were analysed. SDS-sample buffer 3× was added to cells and proteins of the extracts resolved by SDS -PAGE, and transferred onto a polyvinylidene difluoride membrane (Immobilon-P; Millipore, Billerica, MA, USA). The immunoreactive proteins were visualized with the enhanced chemiluminescence detection system (Pierce Chemical, Rockford, IL, USA). Five hundred nanograms of bicistronic vectors, pCTTPwt, pCTTPvar or pCREL, were transfected in HEK293 cells. The luciferase activity was measured to normalize sample loading on PAGE to quantify variations in TTP mRNA isoform translation rather than differences in mRNA levels. Determination of proliferation index was assessed using the 3-[4,5-dimethylthiazol-2yl]-diphenyltetrazolium bromide (MTT) colorimetric assay (Sigma, France) according to the manufacturer's instructions.
Calf intestine alkaline phosphatase treatment
For experiments with calf intestine alkaline phosphatase (CIAP) (New England Biolabs, Ipswich, MA, USA), MDA231 cells were deprived of tetracycline for 24 h before analysis. Cells were then lysed in lysis buffer (1% Triton X-100, 50 mM Tris, pH 8.5, 100 mM NaCl and 0.5 mM EDTA). CIAP (35 U) and its own buffer were added to the lysates for 1 h at 378C. The reaction was stopped by adding SDS-sample buffer.
In vitro transcription/translation
The TNTwT7 Quick-coupled Transcription:Translation System (Promega, Lyon, France) was performed by using pCR2.1-TOPO and pUC vectors (Invitrogen) containing the wild-type or the variant form of Myc-tagged TTP downstream of the T7 promoter. Briefly, same amounts of TTP plasmids (200 ng) were incubated with all the components of the transcription and translation in vitro kit at 308C for 1.5 h as described by the manufacturer's instructions. In vitrotranslated proteins were analyzed by immunoblotting with an anti-myc antibody as already described (5).
Measurement of secreted VEGF and IL8
VEGF and IL8 protein release were measured using an endogen Human IL-8 and VEGF ELISA kit (Pierce Biotechnology, Rockford, IL, USA).
Sucrose-gradient fractionation, polysome-associated RNA analysis and RT -PCR Sucrose-gradient fractionation was performed essentially as described earlier (39) . Briefly, extracts from MCF7 or HS578T cells were prepared by lysis at 48C in extraction buffer (10 mM Tris -HCl, pH 8.0, 140 mM NaCl, 1.5 mM MgCl 2 , 0.5% Nonidet-P40 and 500 U/ml RNAsin), and nuclei were removed by centrifugation (12 000g, 10 s, 488C). The supernatant was supplemented with 20 mM dithiothreitol, 150 mg/ml cycloheximide, 1 mM phenylmethylsulfonyl fluoride and centrifuged (12 000g, 5 min, 48C). The supernatant was layered onto a 5 ml linear sucrose gradient [15 -40% sucrose (w/v) supplemented with 10 mM TrisHCl, pH 7.5, 140 mM NaCl, 1.5 mM MgCl2, 10 mM dithiothreitol, 100 mg/ml cycloheximide] and centrifuged in an SW50.1Ti or SW41Ti rotor (Beckman, Villepinte, France) for 2 h at 160 000g and at 48C, without brake. Fractions of 300 ml were collected and digested with 100 mg of proteinase K in 1% SDS and 10 mM EDTA (30 min, 378C). RNAs were then recovered by phenol -chloroform-isoamyl alcohol extraction, followed by ethanol precipitation. Pellets were washed with 70% ethanol pre-stored at 208C, air-dried and resuspended in appropriate volumes of RNAse-free water. RNAs were analyzed by electrophoresis on 1.2% agarose gels. RT was performed on 1/10 of each fraction using the RevertAid First Strand cDNA Synthesis Kit (Fermentas) with a random hexamer according to the manufacturer's recommendation. The resulting cDNA fragments were PCR-amplified using the Phusion Taq DNA polymerase (Finnzymes) and specific TTP (TTP-F1: 5
′ -GCCCGTCTG GGGTCACCTCCCGCC-3 ′ and TTP-R1: 5 ′ -GGGGTGG CGATTGGCCTGGCGC-3 ′ ) or GAPDH (GAPDH-F1: 5 ′ -CA AGGTCATCCATGACAACTTTG and GAPDH-R1: 5
′ -GT CCACCACCCTGTTGCTGTAG-3 ′ ) primers as control. PCR products of, respectively, 284 and 496 bp for TTP and GAPDH were loaded on a 2% agarose gel and visualized using SYBR Safe DNA gel staining (Invitrogen).
Patients and association studies
Ninety-two women with breast cancer and 89 female controls were analyzed for the presence of the genetic polymorphism NM_003407.2:c.309C . T (rs3746083). The clinical characteristics of 61 patients out of the 92 were already described (40) . All cancer patients had very aggressive tumors carrying an amplification of the HER2 gene (HER2-positive) and were all treated with Herceptin/Trastuzumab, a monoclonal antibody directed against HER2. Genomic DNA was extracted from peripheral blood leukocytes using standard techniques. For SNP c.309C . T (rs3746083), a single amplicon of 400 bp was generated using primers 103F (5 ′ -CGACCATGGAGGGACT GAG-3 ′ ) and 103R (5 ′ -GCCCTGGAGGTAGAACTTGT-3 ′ ) and with the following PCR conditions: 200 ng of genomic DNA, 50 pmol of each primer, 200 mM of each dNTP, 1× buffer, 0.9 U of Taq polymerase (AmpliTaq Gold, Applied Biosystem, Foster City, CA, USA) and 1.5 mM MgCl 2 , in 50 ml of PCR reaction solution. An initial denaturation at 958C for 10 min was followed by amplification for 35 cycles at 958C for 45 s, 628C for 45 s, 728C for 45 s and by a final
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Human Molecular Genetics, 2011, Vol. 20, No. 23 extension at 728C for 10 min. The presence or absence of the variant allele at the c.309C . T locus was assessed by restriction digestion with the enzyme HhaI (according to the manufacturer's recommendations-New England BioLabs). After digestion, the samples were loaded on a 3% agarose gel.
Statistical analysis
Allele frequencies were estimated from genotype data and the patient and control groups were compared by Fisher's exact test for tables with small expected cell counts, setting P ¼ 0.05 as the criterion for statistical significance. The Hardy-Weinberg equilibrium was tested by the x 2 test in both control and patient sets. For the clinical study, comparisons between tumor parameters were performed by ANOVA. Survival estimates were computed using the Kaplan-Meier method and differences between survival times were assessed using the log-rank test. The x 2 test was used to determine associations between patient genotypes, toxicity (hematological, digestive) and response to Trastuzumab-based therapy.
